<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607813</url>
  </required_header>
  <id_info>
    <org_study_id>CLXH254X2101</org_study_id>
    <secondary_id>2015-003421-33</secondary_id>
    <nct_id>NCT02607813</nct_id>
  </id_info>
  <brief_title>Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations</brief_title>
  <official_title>A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway
      Alterations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2016</start_date>
  <completion_date type="Anticipated">March 14, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by incidence and severity of adverse events (AEs), dose interruptions, reductions, and dose intensity.</measure>
    <time_frame>From Cycle 1 Day 1 until 30 days for LXH254 single agent and 150 days for LXH254 in combination with PDR001 post study treatment (expected duration approximately 12 months)</time_frame>
    <description>cycle = 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 single agent only)</measure>
    <time_frame>28 days</time_frame>
    <description>cycle = 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 in combination with PDR001 only)</measure>
    <time_frame>56 days</time_frame>
    <description>cycle =28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Every 2 cycles after starting study treatment until end of treatment; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Every 2 cycles after starting study treatment until end of treatment; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Every 2 cycles after starting study treatment until end of treatment; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Every 2 cycles after starting study treatment until disease progression; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) - only for dose expansion</measure>
    <time_frame>From time of start treatment until the date of death; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LXH254</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: Area Under the Curve (AUC)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: half-life (T1/2)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of pharmacodynamics (PD) marker DUSP6 in tumor tissue and in blood</measure>
    <time_frame>Cycle 1 day 1, 2, 3, 15, and 16; upon disease progression (expected duration approximately 12 months)</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of PDR001</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of PDR001: Area Under the Curve (AUC)</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of PDR001: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of PDR001: Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of PDR001: half-life (T1/2)</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>NSCLC</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose escalation LXH254</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion LXH254: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion LXH254: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion LXH254: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion: LXH254 + PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation LXH254 + PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LXH254</intervention_name>
    <description>pan-RAF inhibitor</description>
    <arm_group_label>Dose escalation LXH254</arm_group_label>
    <arm_group_label>Dose expansion LXH254: Group 1</arm_group_label>
    <arm_group_label>Dose expansion LXH254: Group 2</arm_group_label>
    <arm_group_label>Dose expansion LXH254: Group 3</arm_group_label>
    <arm_group_label>Dose expansion: LXH254 + PDR001</arm_group_label>
    <arm_group_label>Dose escalation LXH254 + PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>Biological: PDR001 anti-PD1 antibody</description>
    <arm_group_label>Dose expansion: LXH254 + PDR001</arm_group_label>
    <arm_group_label>Dose escalation LXH254 + PDR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients participating in this clinical trial must have progressed following
             standard therapy, or for whom, in the opinion of the Investigator, no effective
             standard therapy exists, is tolerated or appropriate.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

          -  Presence of at least one measurable lesion according to RECIST v1.1.

          -  Documented MAPK alteration

        Exclusion Criteria:

        - Prior treatment with a BRAFi, MEKi and/or pan-RAF inihibitors for patients to be enrolled
        in group 1 and 2 in the dose expansion part.

        Exceptions may be made after documented agreement between Novartis and Investigator.

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO.

          -  Any medical condition that would, in the investigator's judgment, prevent the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          -  Patients receiving proton pump inhibitors which cannot be discontinued 3 days prior to
             the start study treatment and for the duration of the study.

          -  Pregnant or nursing (lactating) women

        Additional exclusion criteria for LXH254 in combination with PDR001

          -  History of severe hypersensitivity reactions, which in the opinion of the investigator
             may cause in increased risk of serious infusion reaction.

          -  Known human immunodeficiency virus (HIV).

          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or
             chronic infection.

          -  Active, known or suspected autoimmune disease.

          -  Active infection requiring systemic antibiotic therapy

          -  Patients requiring systemic steroid therapy or any immunosuppressive therapy
             (≥10mg/day prednisone or equivalent) which cannot be discontinued at least 7 days
             prior to first dose of study treatment.

          -  Use of any live vaccines against infectious diseases within 4 weeks of initiation of
             study treatment.

        Other inclusion/exclusion criteria as per protocol may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center SC - LXH254X2101</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alida Beck</last_name>
      <email>becka@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Gopakumar Iyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT M.D Anderson Cancer Center SC - LXH254X2101</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zehra Maloo</last_name>
      <phone>713-563-4426</phone>
      <email>zmaloo@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Filip Janku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Department of Pulmonary Diseases University Medical Center Groningen</last_name>
      <phone>+31 503611546</phone>
      <email>h.j.m.groen@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>H.J.M. Groen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology, Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone_ext>+31 10 7041733</phone_ext>
      <email>m.dejonge@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>M. de Jonge, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LXH254, CRAF, MAPK, solid tumor, PDR001</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

